ArticleVirchows Archiv : an international journal of pathology2026
Clinical pathological features and prognosis of diffuse large B-cell lymphoma initially diagnosed by bone marrow biopsy in patients presenting with peripheral blood cytopenia.
Article in Virchows Archiv : an international journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundDiffuse large B-cell lymphoma (DLBCL) typically presents with lymphadenopathy or extramedullary masses. However, a subset of patients presents with peripheral blood cytopenias, where the diagnosis is primarily established through bone marrow biopsy (BMB). The clinicopathological features and prognosis of this specific presentation remain poorly characterized.
methodsWe retrospectively analyzed 22 patients with DLBCL who presented with peripheral blood cytopenias and were initially diagnosed by BMB. Comprehensive evaluations included BMB histopathology, immunohistochemistry (IHC), bone marrow smear(BMS), flow cytometry, and chromosome karyotype analysis. Clinical data, treatment response, and survival outcomes were assessed. Kaplan-Meier method was performed to identify prognostic factors associated with overall survival.
resultsBMB demonstrated a 100% diagnostic yield, revealing varied cellularity and infiltration patterns (diffuse: 45.45%; interstitial: 22.73%; mixed: 22.73%; nodular: 9.09%). IHC confirmed B-cell lineage (CD20+/PAX5+) and classified 68.18% of cases as non-germinal center B-cell (non-GCB) phenotype by Hans classification. Flow cytometry was positive in 54.55% of cases, and chromosomal abnormalities were detected in 54.55%. On PET/CT, diffuse pattern correlated with immunoblastic morphology and severe infiltration, and high SUVmax with immunoblastic morphology (both p < 0.05). Primary marrow DLBCL (45%) had a significantly longer diagnostic interval than secondary involvement (median 10 vs. 6 days, p = 0.002). Kaplan-Meier analysis showed that high infiltration burden, diffuse pattern, higher fibrosis grade, lack of treatment, diffuse PET/CT pattern, and high SUVmax were associated with poorer overall survival (all p < 0.05).
conclusionBMB is of particular value when extramedullary lesions are absent or difficult to biopsy. Notably, primary marrow DLBCL is associated with diagnostic delays, underscoring the need for heightened clinical suspicion and timely intervention to improve outcomes in this aggressive presentation.
Indexed as
Identifiers
42550238What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.